130 related articles for article (PubMed ID: 30655324)
1. The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER
Pegg HJ; Harrison H; Rogerson C; Shore P
Mol Cancer Res; 2019 May; 17(5):1015-1023. PubMed ID: 30655324
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.
Illendula A; Gilmour J; Grembecka J; Tirumala VSS; Boulton A; Kuntimaddi A; Schmidt C; Wang L; Pulikkan JA; Zong H; Parlak M; Kuscu C; Pickin A; Zhou Y; Gao Y; Mishra L; Adli M; Castilla LH; Rajewski RA; Janes KA; Guzman ML; Bonifer C; Bushweller JH
EBioMedicine; 2016 Jun; 8():117-131. PubMed ID: 27428424
[TBL] [Abstract][Full Text] [Related]
3. Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells.
Won Jeong K; Chodankar R; Purcell DJ; Bittencourt D; Stallcup MR
Mol Endocrinol; 2012 Jun; 26(6):955-66. PubMed ID: 22543272
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of core binding factorβ alters sphingolipid metabolism.
Greer AH; Yong T; Fennell K; Moustafa YW; Fowler M; Galiano F; Ng SW; Berkowitz RS; Cardelli J; Meyers S; Davis JN
J Cell Physiol; 2013 Dec; 228(12):2350-64. PubMed ID: 23813439
[TBL] [Abstract][Full Text] [Related]
5. The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context.
Khan AS; Campbell KJ; Cameron ER; Blyth K
Cells; 2023 Feb; 12(4):. PubMed ID: 36831308
[TBL] [Abstract][Full Text] [Related]
6. The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells.
Mendoza-Villanueva D; Deng W; Lopez-Camacho C; Shore P
Mol Cancer; 2010 Jun; 9():171. PubMed ID: 20591170
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
8. Core Binding Factor-β Knockdown Alters Ovarian Gene Expression and Function in the Mouse.
Wilson K; Park J; Curry TE; Mishra B; Gossen J; Taniuchi I; Jo M
Mol Endocrinol; 2016 Jul; 30(7):733-47. PubMed ID: 27176614
[TBL] [Abstract][Full Text] [Related]
9. Association of Sp3 and estrogen receptor alpha with the transcriptionally active trefoil factor 1 promoter in MCF-7 breast cancer cells.
Li L; Davie JR
J Cell Biochem; 2008 Oct; 105(2):365-9. PubMed ID: 18543253
[TBL] [Abstract][Full Text] [Related]
10. Runx1-Cbfβ facilitates early B lymphocyte development by regulating expression of Ebf1.
Seo W; Ikawa T; Kawamoto H; Taniuchi I
J Exp Med; 2012 Jul; 209(7):1255-62. PubMed ID: 22665574
[TBL] [Abstract][Full Text] [Related]
11. Association of core-binding factor β with the malignant phenotype of prostate and ovarian cancer cells.
Davis JN; Rogers D; Adams L; Yong T; Jung JS; Cheng B; Fennell K; Borazanci E; Moustafa YW; Sun A; Shi R; Glass J; Mathis JM; Williams BJ; Meyers S
J Cell Physiol; 2010 Nov; 225(3):875-87. PubMed ID: 20607802
[TBL] [Abstract][Full Text] [Related]
12. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
13. A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.
Gajulapalli VN; Samanthapudi VS; Pulaganti M; Khumukcham SS; Malisetty VL; Guruprasad L; Chitta SK; Manavathi B
Biochem J; 2016 Apr; 473(8):1047-61. PubMed ID: 26920025
[TBL] [Abstract][Full Text] [Related]
14. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
15. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.
Stender JD; Kim K; Charn TH; Komm B; Chang KC; Kraus WL; Benner C; Glass CK; Katzenellenbogen BS
Mol Cell Biol; 2010 Aug; 30(16):3943-55. PubMed ID: 20547749
[TBL] [Abstract][Full Text] [Related]
17. Core binding factor in the early avian embryo: cloning of Cbfbeta and combinatorial expression patterns with Runx1.
Bollerot K; Romero S; Dunon D; Jaffredo T
Gene Expr Patterns; 2005 Dec; 6(1):29-39. PubMed ID: 16033710
[TBL] [Abstract][Full Text] [Related]
18. Oestrogenic activity of mimosine on MCF-7 breast cancer cell line through the ERα-mediated pathway.
Huq AM; Wai LK; Rullah K; Mohd Aluwi MFF; Stanslas J; Jamal JA
Chem Biol Drug Des; 2019 Mar; 93(3):222-231. PubMed ID: 30251480
[TBL] [Abstract][Full Text] [Related]
19. The Transcription Factor RUNX1 Aggravates Hypoxia-Induced Human Retinal Microvascular Endothelial Cell Dysfunction by Negatively Regulating TFF1 Promoter.
Zhang Y; Qiu S; Liu L; Qiu L
Ann Clin Lab Sci; 2023 May; 53(3):427-437. PubMed ID: 37437926
[TBL] [Abstract][Full Text] [Related]
20. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
